title: Chimeric antigen receptor T cells: power tools to wipe out leukemia and lymphoma.
abstract: Adoptive cell therapy for malignant diseases is showing promise in recent early-phase trials in the treatment of B cell leukemia/lymphoma. Genetically engineered with a tumor-specific chimeric antigen receptor, patient's T cells produce lasting and complete leukemia regression. However, treatment is associated with some toxicity which needs our attention and the field still faces some hurdles at the scientific, technologic and clinical levels. Surmounting these obstacles will establish chimeric antigen receptor T cell therapy as a powerful approach to cure hematologic malignancies, paving the way for the treatment of other common types of cancer in the future.
authors.affiliation: Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
authors.forename: Tobias
authors.initials: T
authors.lastname: Riet
authors.forename: Hinrich
authors.initials: H
authors.lastname: Abken
mesh_terms: D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects / Q000379:methods; D007938:Leukemia / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D008223:Lymphoma / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D011948:Receptors, Antigen, T-Cell / Q000235:genetics* / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000235:genetics* / Q000378:metabolism*
chemical_list: D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins
keywords: T cell; adoptive cell therapy; chimeric antigen receptor; immunotherapy; leukemia; lymphoma